<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01707888</url>
  </required_header>
  <id_info>
    <org_study_id>PEKUPH1201</org_study_id>
    <nct_id>NCT01707888</nct_id>
  </id_info>
  <brief_title>VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer</brief_title>
  <official_title>VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung cancer-a Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS
      major lung resection have been preferred as a standard radical procedure for early stage
      non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major
      lung resection for lung cancer as a real-world study in china.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS
      major lung resection have been preferred as a standard radical procedure for early stage
      non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major
      lung resection for lung cancer as a real-world study in china.This is a multicenter,
      prospective study, aimed To evaluate the short-term and long- term outcome of VATS major lung
      resection for early stage lung cancer. Patients will be followed up every 3 months for 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>morbidity and mortility rate</measure>
    <time_frame>3 moths</time_frame>
    <description>perioperative complications and death rates of the group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3y</time_frame>
    <description>To evaluate Disease Free Survival (DFS) of the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of loco-regional and systemic recurrence</measure>
    <time_frame>3y</time_frame>
    <description>To evaluate the rate of loco-regional and systemic recurrence of the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>to evaluate the pulmonary function as measured by expiratory flow rate of the group 6 months postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay.</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>to evaluate the postoperative hospital stay of the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative drainage duration</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>to evaluate the postoperative drainage duration of the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>to evaluate the overall survival rate of the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>converted rate</measure>
    <time_frame>3 months</time_frame>
    <description>the rate of converted thoracotomy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>major lung resection</arm_group_label>
    <description>Patients undergo major lung resection by thoracoscopy/VATS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopy/VATS</intervention_name>
    <description>Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.</description>
    <arm_group_label>major lung resection</arm_group_label>
    <other_name>Minimal invasive surgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        clinical early stage(I/II) lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Preoperative criteria:

        i) non-small cell lung cancer is suspected, ii) clinical stage I/II (3) Intraoperative
        criteria: i) Histologically confirmed NSCLC, ii) resected by VATS or converted open
        lobectomy,sleeve lobectomy or pneumonectomy and nodal dissection/sampling.

        (4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).

        (5) No prior chemotherapy or radiation therapy for any malignant diseases. (6) Expected
        postoperative FEV1.0&gt;=800 mL and PaO2&gt;=65 torr. (7) Performance status of 0 or 1. (8)
        Sufficient organ functions. (9) Written informed consent.

        Exclusion Criteria:

          1. Active bacterial or fungous infection.

          2. Simultaneous or metachronous (within the past 5 years) double cancers.

          3. Women during pregnancy or breast-feeding.

          4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.

          5. Psychosis.

          6. Systemic steroids medication.

          7. Uncontrollable diabetes mellitus.

          8. Uncontrollable hypertension.

          9. History of severe heart disease, heart failure, myocardial infarction within the past
             6 months or attack of angina pectoris within the past 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fan Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhao Xi Sui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Wang, MD</last_name>
    <phone>88324078</phone>
    <email>Jwangmd@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Songlei Ou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keneng Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Haidian Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqing Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhi Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking university people's hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

